GlaxoSmithKline Plc (GSK):企業の財務・戦略的SWOT分析

◆英語タイトル:GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY0590
◆発行会社(調査会社):GlobalData
◆発行日:2019年12月
◆ページ数:92
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

GlaxoSmithKline Plc (GSK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GlaxoSmithKline Plc (GSK) is a healthcare company that focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc Key Recent Developments

Nov 22,2019: Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management
Nov 21,2019: Bayer and Shionogi Europe to keynote Veeva Commercial & Medical Summit, Europe
Nov 14,2019: Viome announces scientific collaboration with GSK to research the prevention of specific chronic diseases
Oct 21,2019: Bavarian Nordic to acquire travel vaccines from GSK
Oct 09,2019: GSK and Lyell partner to develop cell therapies for cancer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
GlaxoSmithKline Plc – Key Facts
GlaxoSmithKline Plc – Key Employees
GlaxoSmithKline Plc – Key Employee Biographies
GlaxoSmithKline Plc – Major Products and Services
GlaxoSmithKline Plc – History
GlaxoSmithKline Plc – Company Statement
GlaxoSmithKline Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
GlaxoSmithKline Plc – Business Description
Business Segment: Consumer Healthcare
Overview
Performance
Key Stats
Business Segment: Pharmaceuticals
Overview
Performance
Key Stats
Business Segment: Vaccines
Overview
Performance
Key Stats
Geographical Segment: Rest of World
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US
Performance
R&D Overview
GlaxoSmithKline Plc – Corporate Strategy
GlaxoSmithKline Plc – SWOT Analysis
SWOT Analysis – Overview
GlaxoSmithKline Plc – Strengths
GlaxoSmithKline Plc – Weaknesses
GlaxoSmithKline Plc – Opportunities
GlaxoSmithKline Plc – Threats
GlaxoSmithKline Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
GlaxoSmithKline Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 22, 2019: Exagen extends agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management
Nov 21, 2019: Bayer and Shionogi Europe to keynote Veeva Commercial & Medical Summit, Europe
Nov 14, 2019: Viome announces scientific collaboration with GSK to research the prevention of specific chronic diseases
Oct 21, 2019: Bavarian Nordic to acquire travel vaccines from GSK
Oct 09, 2019: GSK and Lyell partner to develop cell therapies for cancer
Sep 26, 2019: GSK to invest $120m to expand manufacturing facility in US
Sep 13, 2019: Vectura provides update on GSK Litigation
Sep 11, 2019: GSK to buy Sitari Pharmaceuticals from Avalon Ventures
Sep 05, 2019: New FDI World Dental Federation Care Pathway promotes dentist-patient collaboration to manage partial tooth loss
Sep 04, 2019: Medicines Manufacturing Innovation Centre secures £42 million of funding for new manufacturing centre
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
GlaxoSmithKline Plc, Key Facts
GlaxoSmithKline Plc, Key Employees
GlaxoSmithKline Plc, Key Employee Biographies
GlaxoSmithKline Plc, Major Products and Services
GlaxoSmithKline Plc, History
GlaxoSmithKline Plc, Other Locations
GlaxoSmithKline Plc, Subsidiaries
GlaxoSmithKline Plc, Joint Venture
GlaxoSmithKline Plc, Key Competitors
GlaxoSmithKline Plc, Ratios based on current share price
GlaxoSmithKline Plc, Annual Ratios
GlaxoSmithKline Plc, Annual Ratios (Cont...1)
GlaxoSmithKline Plc, Annual Ratios (Cont...2)
GlaxoSmithKline Plc, Interim Ratios
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
GlaxoSmithKline Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
GlaxoSmithKline Plc, Performance Chart (2014 - 2018)
GlaxoSmithKline Plc, Ratio Charts
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[GlaxoSmithKline Plc (GSK):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sibur Holding:企業の戦略的SWOT分析
    Sibur Holding - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Ultra Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Ultra Petroleum Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Ultra Petroleum Corp (Ultra) is an independent upstream company, which develops, produces, operates, explores, and acquires oil and natural gas properties. It develops long-life natural gas rese …
  • Venture Global LNG Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Venture Global LNG Inc (VGLI) is an exporter of american-produced liquefied natural gas. The company owns and manages two Louisiana-based export projects Calcasieu Pass and Plaquemines. The company through subsidiary Venture Global Calcasieu Pass, LLC, operates Calcasieu Pass project, which …
  • PT Total Bangun Persada Tbk:企業の戦略・SWOT・財務情報
    PT Total Bangun Persada Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Total Bangun Persada Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Netcare Ltd (NTC):企業の財務・戦略的SWOT分析
    Summary Netcare Ltd (Netcare) is a healthcare service provider that offers patient care services. The center provides medical facilities and treatments in the fields of breast care, oncology, orthopedics, renal care, transplants and weight management. Its facilities include medicross centers, netcar …
  • PPL Corp (PPL):企業の財務・戦略的SWOT分析
    PPL Corp (PPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Valener Inc (VNR):企業の戦略的SWOT分析
    Valener Inc (VNR) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Twenty-First Century Fox, Inc.:企業の戦略・SWOT・財務情報
    Twenty-First Century Fox, Inc. - Strategy, SWOT and Corporate Finance Report Summary Twenty-First Century Fox, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Marafiq:企業の戦略的SWOT分析
    Marafiq - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Zai Lab Ltd (ZLAB):製薬・医療:M&Aディール及び事業提携情報
    Summary Zai Lab Ltd (Zai Lab) is a biopharmaceutical company that discovers, develops and manufactures transformative medicines for cancer, autoimmune and infectious diseases. The company’s pipeline products include ZL-2306, ZL-2401, FPA144, EXT2514SUL, ZL-2301, ZL-3101, ZL-2302 and ZL-1101. It deve …
  • Eagle Pharmaceuticals Inc (EGRX):企業の財務・戦略的SWOT分析
    Eagle Pharmaceuticals Inc (EGRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Medistim ASA (MEDI):製品パイプライン分析
    Summary MediStim ASA (MediStim) is a medical device company that manufactures and markets medical products related to cardiac, vascular and transplant surgeries. The company offers products that include MiraQ cardiac, MiraQ vascular, MiraQ ultimate system, imaging probes, flow probes, VeriQ C system …
  • Aviakompaniya Sibir” OAO (P):企業の戦略・SWOT・財務情報
    Aviakompaniya Sibir'' OAO (P) - Strategy, SWOT and Corporate Finance Report Summary Aviakompaniya Sibir'' OAO (P) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Adaptimmune Therapeutics Plc (ADAP):製薬・医療:M&Aディール及び事業提携情報
    Summary Adaptimmune Therapeutics Plc (Adaptimmune), formerly Adaptimmune Therapeutics Limited, is a clinical stage biopharmaceutical company that develops innovative T-cell therapy products for the treatment of cancer. It harnesses the proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) …
  • GenomicTree Co Ltd (228760):企業の製品パイプライン分析
    Summary GenomicTree Co Ltd (GenomicTree) is a medical device company that develops and commercializes diagnostic products for the screening and diagnosis of cancer. The company also provides non-invasive cancer molecular diagnostic product. Its products are used in the detection of colorectal, lung …
  • Tallgrass Energy Partners, LP (TEP)-石油・ガス分野:企業M&A・提携分析
    Summary Tallgrass Energy Partners, LP (Tallgrass Energy) is a midstream oil and gas company. It owns, operates, acquires and develops midstream energy assets in North America. The company offers natural gas transportation and storage services through its pipeline and natural gas processing assets to …
  • National Shipping Company of Saudi Arabia (4030):石油・ガス:M&Aディール及び事業提携情報
    Summary National Shipping Company of Saudi Arabia (Bahri) is a joint stock shipping company, which purchases, charters and operates shipping vessels for the transportation of crude oil, liquefied petroleum gas (LPG), petrochemicals, general cargo, passengers and dry bulk. It operates a fleet of very …
  • CGU Insurance Limited:企業の戦略・SWOT・財務情報
    CGU Insurance Limited - Strategy, SWOT and Corporate Finance Report Summary CGU Insurance Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Isofol Medical AB (ISOFOL)-製薬・医療分野:企業M&A・提携分析
    Summary Isofol Medical AB (Isofol) is a clinical stage pharmaceutical company developing folate-based therapies for the treatment of cancer patients. The company’s clinical lead candidate Modufolin, a metabolite is under clinical phase I/II development being evaluated for the treatment of colorectal …
  • Tri-State Generation and Transmission Association Inc:企業の戦略的SWOT分析
    Tri-State Generation and Transmission Association Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key com …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆